ResMed Inc. 10-Q Filing Summary
Business Context and Reporting Period
Company: ResMed Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2006
Business Overview: ResMed designs, manufactures, and markets equipment for the diagnosis and treatment of sleep-disordered breathing (including obstructive sleep apnea) and other respiratory disorders. Operations include manufacturing in Australia, Germany, France, and the U.S., with major distribution sites globally.
Key Financial Metrics
| Metric (in thousands, except per share) | Three Months Ended Dec 31, 2006 | Six Months Ended Dec 31, 2006 |
|---|---|---|
| Net Revenues | $178,428 | $342,033 |
| Gross Profit | $111,758 | $213,054 |
| Gross Margin | 63% | 62% |
| Operating Income | $40,692 | $76,008 |
| Net Income | $28,995 | $53,994 |
| Diluted EPS | $0.37 | $0.69 |
| Cash from Operations (6mo) | $43,695 | |
| Cash & Equivalents (Dec 31, 2006) | $232,668 | |
| Total Debt (Current + Long-term) | $133,548 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 22% for the quarter and 25% for the six-month period compared to the prior year. Growth was driven by increased unit sales of flow generators, masks, and accessories, as well as favorable foreign currency movements (+$5.9M impact in the quarter).
- Profitability: Net income rose 30% for the quarter ($29.0M vs. $22.3M) and 39% for the six months ($54.0M vs. $38.8M). Diluted EPS increased from $0.30 to $0.37 for the quarter.
- Expense Trends:
- SG&A: Increased 17% (quarter) and 18% (six months) due to personnel growth, infrastructure investment, and currency impacts.
- R&D: Increased 40% (quarter) and 35% (six months) driven by increased personnel and technical assessments for new products.
- Restructuring: No restructuring expenses were incurred in the current period, compared to $1.1M in the prior six-month period.
- Balance Sheet: Inventories increased 32% to $141.9M to support sales growth and new product introductions. Accounts receivable increased 24% to $143.6M.
Guidance, Outlook, and Risks
- Outlook: Management expects SG&A to remain in the range of 31% to 34% of net revenue and R&D to remain in the range of 6% to 7% of net revenue.
- Capital Projects: Completed construction of new R&D and office facilities in Sydney ($12.0M). Plans to commence an extension to the Sydney manufacturing facility in Q1 2007, estimated at $11.9M.
- Acquisitions: Acquired Western Medical Marketing (WMM) for $0.3M in October 2006. Accrued additional earn-out payments for prior acquisitions (PolarMed and Hoefner) totaling $1.3M based on performance milestones.
- Risks & Contingencies:
- Foreign Currency: Significant exposure to AUD and EUR fluctuations; hedging program in place but deemed "non-effective" for accounting purposes.
- Legal: Ongoing tax audit in Germany (1996-1998) and a patent inventorship dispute in Munich; management does not expect material adverse effects.
- Debt Covenants: Company is in compliance with all debt covenants, including leverage ratios and fixed charge coverage.
Investor Verification Checklist
- Inventory Levels: Verify if the 32% increase in inventory aligns with sales velocity to assess obsolescence risk.
- Foreign Exchange Impact: Monitor the impact of currency fluctuations on future margins, as currency movements contributed significantly to recent revenue growth.
- Debt Structure: Review the Syndicated Facility tranches (A, B, and C) and their respective maturity dates (2009-2011) and interest rate margins.
- Acquisition Milestones: Track future earn-out payments for PolarMed, Pulmomed, and Hoefner, which could increase goodwill and cash outflows.
- Capital Expenditures: Confirm funding sources for the upcoming $11.9M Sydney facility extension.